Form 10-K ALNYLAM PHARMACEUTICALS, For: Dec 31
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- Abbott plans to spin off its nutrition unit as a standalone public company
- Alphabet shares drop ahead of earnings next week
- AMD shares fall amid AI chip sector selloff
- Bloom Energy Corp. (BE) Tops Q3 EPS by 25c, Beats on Revenue; Offers FY26 Guidance
- Nasdaq leads Wall Street gains as SpaceX, Super Micro boost AI sentiment
Alnylam Pharmaceuticals (ALNY) PT Lowered to $175 at BMO Capital
February 11, 2022 7:21 AM ESTBMO Capital analyst Gary Nachman lowered the price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) to $175.00 (from $180.00) while maintaining a Market Perform rating.
The analyst commented, "Solid 4Q product revenue was preannounced as key commercial products (Onpattro/Givlaari/Oxlumo) continue good momentum with increased... More



